In an editorial this summer published in Personalized Medicine, authors from The Michael J. Fox Foundation for Parkinson’s Research and J. William Langston, M.D., chief scientific officer and founder of The Parkinson’s Institute, outlined a strategy to advance precision medicine in Parkinson’s disease (PD).
Lead author Todd Sherer, Ph.D., CEO of The Michael J. Fox Foundation and his co-authors believe that by pivoting from traditional definitions of disease to profile pathology by genetic and molecular changes, neurodegeneration researchers can design and test more targeted therapies with higher likelihood of success.
